Clinical trials
Completed trials in Russia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
4,815 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 9 |
| 2001 | 19 |
| 2002 | 35 |
| 2003 | 78 |
| 2004 | 99 |
| 2005 | 124 |
| 2006 | 181 |
| 2007 | 222 |
| 2008 | 253 |
| 2009 | 261 |
| 2010 | 241 |
| 2011 | 283 |
| 2012 | 283 |
| 2013 | 270 |
| 2014 | 249 |
| 2015 | 257 |
| 2016 | 278 |
| 2017 | 298 |
| 2018 | 285 |
| 2019 | 261 |
| 2020 | 311 |
| 2021 | 220 |
| 2022 | 119 |
| 2023 | 80 |
| 2024 | 51 |
| 2025 | 24 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 4,815 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 264 |
| GlaxoSmithKline | 221 |
| Hoffmann-La Roche | 221 |
| AstraZeneca | 213 |
| Sanofi | 170 |
| Pfizer | 151 |
| Boehringer Ingelheim | 144 |
| Bristol-Myers Squibb | 125 |
| Bayer | 115 |
| Eli Lilly and Company | 114 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 274 |
| Arthritis, Rheumatoid | 159 |
| Breast Neoplasms | 150 |
| Diabetes Mellitus | 138 |
| Asthma | 129 |
| Pulmonary Disease, Chronic Obstructive | 126 |
| Carcinoma, Non-Small-Cell Lung | 122 |
| COVID-19 | 107 |
| Neoplasms | 105 |
| Schizophrenia | 96 |
Trials
Showing 76 to 100 of 4,815. Each trial links to its page on Pharma Observatory.
4,715 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.